Sellas life sciences triggers interim analysis in phase 3 regal trial of gps in acute myeloid leukemia

-  study reaches pre-specified threshold of 60 events (deaths) initiating the interim analysis – -  regal independent data monitoring committee to perform interim analysis in january 2025 - -  company to host webcast call today at 9:00 am et new york, dec. 10, 2024 (globe newswire) -- sellas life sciences group, inc. (nasdaq: sls) (“sellas'' or the “company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the pre-specified threshold of 60 events (deaths) has been reached in its ongoing phase 3 regal clinical trial of galinpepimut-s (gps) in acute myeloid leukemia (aml), triggering the interim analysis to be conducted by the independent data monitoring committee (idmc). the idmc will conduct a thorough review of the current regal data, and the interim analysis will provide an assessment of efficacy, futility as well as safety of gps.
GPS Ratings Summary
GPS Quant Ranking